Briefing
MolDX lists two assays for monitoring response to immune-checkpoint inhibitor therapy
The MolDX billing article A58434, in the revision effective January 1, 2026, lists Signatera for monitoring response to immune-checkpoint inhibitor therapy in advanced solid tumors and Guardant Response for inoperable or metastatic solid tumors.